Patents by Inventor Gilles Ouvry

Gilles Ouvry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170247353
    Abstract: Compounds having formula (I) are described. Also described, are methods of using these compounds to treat diseases, conditions, and disorders.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 31, 2017
    Inventors: Gilles OUVRY, Craig Steven HARRIS, Yushma BHURRUTH-ALCOR
  • Patent number: 9657008
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: May 23, 2017
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
  • Publication number: 20160137634
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: August 31, 2015
    Publication date: May 19, 2016
    Applicant: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie, Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
  • Patent number: 9156831
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: October 13, 2015
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Gilles Ouvry, Christine Marie Paul Lambert-Van Der Brempt, Craig Steven Harris, David Berry, Gary Peter Tomkinson, Gary Patrick Reid
  • Publication number: 20140206700
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe BARLAAM, Benedicte DELOUVRIE, Gilles OUVRY, Christine Marie, Paul, LAMBERT-VAN DER BREMPT, Craig Steven HARRIS, David BERRY, Gary Peter TOMKINSON, Gary Patrick REID
  • Patent number: 8017611
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: September 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
  • Publication number: 20110183975
    Abstract: The present invention relates to a compound of formula I: wherein: R1 is C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, or —COR1x, where the C1-6 alkyl, C3-8 cycloalkyl, aryl, and heterocyclyl may be substituted; and R1x is C3-8 cycloalkyl, aryl, or heterocyclyl, any of which may be substituted; R2, R3, R4, R5, R6, and R7 are each independently hydrogen, halogen, C1-6 alkyl, or aryl, where the C1-6 alkyl or aryl may be substituted; R8 is hydrogen, C1-6 alkyl, aryl, or heterocyclyl, any of which may be substituted; or a pharmaceutically acceptable salt or ester thereof.
    Type: Application
    Filed: September 28, 2009
    Publication date: July 28, 2011
    Inventors: Yasuhiro Goto, Takeshi Sagara, Weiming Fan, Thomas F. N. Hacell, Matthew G. Jenks, Michael J. Malaska, Joseph A. Moore, III, Gilles Ouvry, Bharathi Pandi, Michael R. Peel, Kimberty M. Steward
  • Publication number: 20090118305
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter